# BIOLARGO, INC. (BLGO) · Edgar & Edgarette company card

> Biolargo (BLGO) saw revenue fall 56.3% in FY2025 to $8 million, operating margin -191% against a 0.1% median for chemicals & allied products, equity 48.6% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 880242 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/BLGO) · [JSON](https://www.pops4.com/boards/company/BLGO.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $8M |
| Revenue growth, 1 year | -56.3% |
| Revenue growth per year | 32.3% |
| Operating margin | -191.3% (prior year -24.4%) |
| Net margin | -195.6% |
| Operating cash flow | −$8M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $4M |
| Long-term debt | $2M |
| Total assets | $8M |
| Total equity | $4M |
| Equity ÷ assets | 48.6% |
| Return on equity | -375.8% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -74.61 (distress zone)
- Piotroski F: 1 of 9 (weak)
- Beneish M: -8.08 (below the −1.78 line)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -191.3% in FY2025; revenue is hard to predict: its 80% range is ±76%
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $7.8M (FY2025), total debt $2.1M. Experience: revenue down 56.3% on the year, up 32.3% a year over 4 years; operating margin -191.3%, down from -24.4%. Soundness: equity 48.6% of assets, return on equity -375.8%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $2.2M and $15.9M next year (method v4.1: its own 6-year record of growth weighed at 63% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $1.9M to $18.3M. A statistical range, not company guidance. Against peers (9 filers, $50M+ revenue, chemicals & allied products): operating margin -191.3% against a 0.1% median; growth -56.3% against 0.4%.

Range logged 2026-09-29, receipt 4293e4bc117d5329, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

No warning filings in the window.

## Recent filings

- 8-K · filed 2026-11-02 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/880242/000143774926034271/0001437749-26-034271-index.htm)
- DEF 14A · filed 2026-10-19 · [filing](https://www.sec.gov/Archives/edgar/data/880242/000143774926032868/0001437749-26-032868-index.htm)
- 8-K · filed 2026-09-11 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/880242/000143774926030124/0001437749-26-030124-index.htm)
- 10-Q · filed 2026-08-14 · [filing](https://www.sec.gov/Archives/edgar/data/880242/000143774926028023/0001437749-26-028023-index.htm)
- 10-Q · filed 2026-05-15 · [filing](https://www.sec.gov/Archives/edgar/data/880242/000143774926017391/0001437749-26-017391-index.htm)
- 8-K · filed 2026-05-06 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/880242/000143774926014996/0001437749-26-014996-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000880242.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=880242

## Cite

POPS4, Edgar & Edgarette: BIOLARGO, INC. (BLGO) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/BLGO. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.